ConductScience.org, home

Paper309306

CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization.

English AR and 4 others. Antimicrob Agents Chemother, 1978. Cited by 379 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization. Papers, record 309306. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/309306

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization.
PubMed
Journal
Antimicrob Agents Chemother
PubMed
Year
1978
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
379
iCite
Relative citation ratio, by iCite
13.8
iCite
Revised in PubMed
2021-05-26
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1English ARA R
2Retsema JAJ A
3Girard AEA E
4Lynch JEJ E
5Barth WEW E

Source PubMed

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
BacteriaMajor topic
ThiazolesMajor topic
beta-Lactamase InhibitorsMajor topic
Ampicillin
Drug Therapy, Combination
beta-Lactams

Source PubMed

References5

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
114,480,578Micro-iodometric assay for penicillinase.Biochem J1962https://conductscience.org/library/papers/14480578PubMed
2879,738Clavulanic acid: a beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus.Antimicrob Agents Chemother1977https://conductscience.org/library/papers/879738PubMed
35,195,741Effects of beta-lactamase from gram-negative organisms on cephalosporins and penicillins.Antimicrob Agents Chemother (Bethesda)1968https://conductscience.org/library/papers/5195741PubMed
4783,110The beta-lactamases of gram-negative bacteria and their role in resistance to beta-lactam antibiotics.J Antimicrob Chemother1976https://conductscience.org/library/papers/783110PubMed
5950,324Naturally-occurring beta-lactamase inhibitors with antibacterial activity.J Antibiot (Tokyo)1976https://conductscience.org/library/papers/950324PubMed

Cited by99

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 379 citations.

PMIDTitleJournalYearIn PapersSource
42,239,032Cooperative antibiotic response in coupled biofilm and planktonic E. faecalis communities.bioRxiv2026https://conductscience.org/library/papers/42239032PubMed
41,907,167Therapeutic challenges and emerging strategies against carbapenem-resistant Acinetobacter baumannii.Curr Res Microb Sci2026https://conductscience.org/library/papers/41907167PubMed
41,113,112Structural insights into the activity of carbapenemases: understanding the mechanism of action of current inhibitors and informing the design of new carbapenem adjuvants.RSC Med Chem2025https://conductscience.org/library/papers/41113112PubMed
40,952,390Targeting mycobacterial transpeptidases: evaluating the roles of Ldt and PBP inhibition in suppressing Mycobacterium smegmatis.Antimicrob Agents Chemother2025https://conductscience.org/library/papers/40952390PubMed
40,734,664
Amphiphilic nebramine analogs synergize with β-lactam/β-lactamase inhibitor combinations, including cefepime-taniborbactam and meropenem-xeruborbactam against metallo-β-lactamase-carrying Pseudomonas aeruginosa.
RSC Med Chem2025https://conductscience.org/library/papers/40734664PubMed
38,188,094Mechanism-Based Enzyme Inactivation Using an Allyl Sulfoxide-Allyl Sulfenate Ester Rearrangement1.J Am Chem Soc1980https://conductscience.org/library/papers/38188094PubMed
37,125,470Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species.Clin Infect Dis2023https://conductscience.org/library/papers/37125470PubMed
35,486,701Studies on enmetazobactam clarify mechanisms of widely used β-lactamase inhibitors.Proc Natl Acad Sci U S A2022https://conductscience.org/library/papers/35486701PubMed
34,250,791The G132S Mutation Enhances the Resistance of Mycobacterium tuberculosis β-Lactamase against Sulbactam.Biochemistry2021https://conductscience.org/library/papers/34250791PubMed
34,129,337Metallo-β-lactamases in the Age of Multidrug Resistance: From Structure and Mechanism to Evolution, Dissemination, and Inhibitor Design.Chem Rev2021https://conductscience.org/library/papers/34129337PubMed
33,199,391Structural Investigations of the Inhibition of Escherichia coli AmpC β-Lactamase by Diazabicyclooctanes.Antimicrob Agents Chemother2021https://conductscience.org/library/papers/33199391PubMed
32,591,801Discovery and characterization of New Delhi metallo-β-lactamase-1 inhibitor peptides that potentiate meropenem-dependent killing of carbapenemase-producing Enterobacteriaceae.J Antimicrob Chemother2020https://conductscience.org/library/papers/32591801PubMed
31,150,547Antibiotic resistance breakers: current approaches and future directions.FEMS Microbiol Rev2019https://conductscience.org/library/papers/31150547PubMed
30,837,684Interplay between β-lactamases and new β-lactamase inhibitors.Nat Rev Microbiol2019https://conductscience.org/library/papers/30837684PubMed
30,061,509Tackling the Antibiotic Resistance Caused by Class A β-Lactamases through the Use of β-Lactamase Inhibitory Protein.Int J Mol Sci2018https://conductscience.org/library/papers/30061509PubMed
27,329,032β-Lactams and β-Lactamase Inhibitors: An Overview.Cold Spring Harb Perspect Med2016https://conductscience.org/library/papers/27329032PubMed
27,000,559Targeting Antibiotic Resistance.Angew Chem Int Ed Engl2016https://conductscience.org/library/papers/27000559PubMed
24,272,507The molecular basis for the mode of action of Beta-lactam antibiotics and mechanisms of resistance.Pharm Res1985https://conductscience.org/library/papers/24272507PubMed
24,100,499Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012).Antimicrob Agents Chemother2013https://conductscience.org/library/papers/24100499PubMed
23,547,944Homology modeling and virtual screening approaches to identify potent inhibitors of VEB-1 β-lactamase.Theor Biol Med Model2013https://conductscience.org/library/papers/23547944PubMed

See all 99 cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/309306

GET https://conductscience.org/api/papers/v1/309306/cited_by?page=2